News


DateTitle
05-07-2011Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
06-05-2011Dr. Leon Hooftman appointed Chief Medical Officer as Opsona Therapeutics transitions into the clinic
06-05-2011European Commision awards EUR 5.9M to Opsona Therapeutics for clinical development of lead drug candidate OPN-305
06-05-2011Opsona Therapeutics appoints Chairman Dr. Bernd R. Seizinger as Executive Chairman; Dr. Mark Heffernan resigns as CEO but remains as Non-Executive Director
09-10-2009Opsona Therapeutics Founder Awarded Prestigious Boyle Medal
18-05-2009Roche Venture Fund, Enterprise Ireland Commit €3.3 m To Opsona Series B Financing
04-03-2009OPSONA & LONZA enter into manufacturing agreement for the production of a monoclonal antibody OPN-305 developed by OPSONA Therapeutics Ltd.
22-02-2009OPSONA, CSL Form Vaccine Adjuvant R&D Collaboration Targeting Infectious Diseases And Oncology
18-02-2009OPSONA Therapeutics closes €18M funding
02-02-2009Antitope Ltd & Opsona Therapeutics Ltd announce successful Composite Human Antibody project
24-11-2008Opsona Therapeutics Appoints new VP of Research
19-05-2008Opsona's CEO is a finalist for the 2008 Ernst & Young Entrepreneur of the Year competition.
15-05-2008Opsona Receives Milestone Payments Under Wyeth Collaboration
21-11-2007Opsona Therapeutics In-Licenses Novel Anti-inflammatory Molecule from Nestlé
15-03-2006Opsona and Phylogica enter into a drug discovery collaboration
13-02-2006Opsona Therapeutics Announces a Collaboration with Wyeth on Toll-Like Receptors
24-02-2005Opsona completes €6.6m financing agreement
01-01-2005Opsona Therapeutics appoints CFO & Senior Business Development Executive to Management Team